Kristin Moberg Aakre

Kristin Moberg Aakre

Auto-generated profile, based on publicly available information

Kristin Moberg Aakre

Department of Medical Biochemistry and Pharmacology and Department of Heart Disease, Haukeland University Hospital , Bergen

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 June 2022 in Clinical Chemistry
Verified
Journal Article
Open access
PDF file
KAKristin M Aakre
Kristin M Aakre
ASAmy K Saenger
Amy K Saenger
RBRick Body
Rick Body
PCPaul St Georges University of Collinson
Paul St Georges University of Collinson
OHOla Hammarsten
Ola Hammarsten
FAFred S Apple
Fred S Apple
The International Federation of Clinical Chemistry Committee on Clinical Application of Cardiac Bio-Markers provides evidence-based educational documents to facilitate uniform interpretation and utilization of cardiac biomarkers in clinical laboratories and practice. The committee’s goals are to improve the understanding of certain key analytical and clinical aspects of cardiac biomarkers and how these may interplay in clinical practice. Measurement of high-sensitivity cardiac troponin (hs-cTn) assays is a cornerstone in the clinical evaluation of patients with symptoms and/or signs of acute cardiac ischemia. To define myocardial infarction, the Universal Definition of Myocardial Infarction requires patients who manifest with features suggestive of acute myocardial ischemia to have at least one cTn concentration above the sex-specific 99th percentile upper reference limit (URL) for hs-cTn assays and a dynamic pattern of cTn concentrations to fulfill the diagnostic criteria for MI. This special report provides an overview of how hs-cTn 99th percentile URLs should be established, including recommendations about prescreening and the number of individuals required in the reference cohort, how statistical analysis should be conducted, optimal preanalytical and analytical protocols, and analytical/biological interferences or confounds that can affect accurate determination of the 99th percentile URLs. This document also provides guidance and solutions to many of the issues posed.

1 June 2014 in Clinical Chemistry
Verified
Journal Article
Open access
PDF file
KAKristin M. Aakre
Kristin M. Aakre
TRThomas Røraas
Thomas Røraas
PPPer Hyltoft Petersen
Per Hyltoft Petersen
ESEinar Svarstad
Einar Svarstad
HSHilde Sellevoll
Hilde Sellevoll
SSSverre Sandberg
Sverre Sandberg
BACKGROUND: Myocardial infarction (MI) is diagnosed by the finding of a single cardiac troponin value above the 99th percentile and a significant time-dependent change in cardiac troponin concentration. The aim of this study was to determine the 90-min and weekly biological variations, the reference change value (RCV), and the index of individuality (II) of high-sensitivity cardiac troponin T (hs-cTnT) (Roche Diagnostics) and hs-cTnI (Abbott Diagnostics) in patients receiving hemodialysis (HD) and in healthy individuals. METHOD: Blood samples were collected from 19 HD patients (on an HD-free day) and 20 healthy individuals at 90-min intervals over a 6-h period (between 08:30 and 14:30) and before the midweek HD treatment for 10 weeks. The within-person variation (CVi), between-person variation, RCV, and II were calculated. RESULTS: During the 6-h sampling period, the concentrations of hs-cTnT (both groups) and hs-cTnI (HD patients only) decreased on average by 0.8% to 1.7% per hour, respectively. These declining trends were included in the calculation of a 90-min asymmetric RCV: −8%/+5% in HD patients (hs-cTnT), −18%/+21% in HD patients (hs-cTnI), −27%/+29% in healthy individuals (hs-cTnT), and −39%/+64% in healthy individuals (hs-cTnI). The II was low in both groups for both assays. The weekly CVi values were approximately 8% (hs-cTnT) and 15% (hs-cTnI) in both groups. CONCLUSIONS: When using a cardiac troponin change of 20%–50% to diagnose an MI, the false-positive rate is likely to be lower for the hs-cTnT assay than for the hs-cTnI assay. The low II suggests that use of a diagnostic cutoff value can be omitted.

5 January 2023 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Open access
PDF file
OHOla Hammarsten
Ola Hammarsten
JWJanet V. Warner
Janet V. Warner
LLLeo Lam
Leo Lam
PKPeter Kavsak
Peter Kavsak
BLBertil Lindahl
Bertil Lindahl
FAFred S. Apple
Fred S. Apple
The International Federation of Clinical Chemistry Committee on Clinical Applications of Cardiac Biomarkers (IFCC C-CB) provides educational documents to facilitate the interpretation and use of cardiac biomarkers in clinical laboratories and practice. Our aim is to improve the understanding of certain key analytical and clinical aspects of cardiac biomarkers and how these may interplay. Measurements of cardiac troponin (cTn) have a prominent place in the clinical work-up of patients with suspected acute coronary syndrome. It is therefore important that clinical laboratories know how to recognize and assess analytical issues. Two emerging analytical issues resulting in falsely high cTn concentrations, often several fold higher than the upper reference limit (URL), are antibody-mediated assay interference due to long-lived cTn-antibody complexes, called macrotroponin, and crosslinking antibodies that are frequently referred to as heterophilic antibodies. We provide an overview of antibody-mediated cTn assay interference and provide recommendations on how to confirm the interference and interpret the results.

5 October 2012 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
KAKristin M. Aakre
Kristin M. Aakre
MLMichel R. Langlois
Michel R. Langlois
JWJoseph Watine
Joseph Watine
JBJulian H. Barth
Julian H. Barth
HBHannsjörg Baum
Hannsjörg Baum
WOWytze P. Oosterhuis
Wytze P. Oosterhuis
Background: Correct information provided by guidelines may reduce laboratory test related errors during the pre-analytical, analytical and post-analytical phase and increase the quality of laboratory results. Methods: Twelve clinical practice guidelines were reviewed regarding inclusion of important laboratory investigations. Based on the results and the authors’ experience, two checklists were developed: one comprehensive list including topics that authors of guidelines may consider and one consisting of minimal standards that should be covered for all laboratory tests recommended in clinical practice guidelines. The number of topics addressed by the guidelines was related to involvement of laboratory medicine specialists in the guideline development process. Results: The comprehensive list suggests 33 pre- analytical, 37 analytical and 10 post-analytical items. The mean percentage of topics dealt with by the guidelines was 33% (median 30%, range 17%–55%) and inclusion of a laboratory medicine specialist in the guideline committee significantly increased the number of topics addressed. Information about patient status, biological and analytical interferences and sample handling were scarce in most guidelines even if the inclusion of a laboratory medicine specialist in the development process seemingly led to increased focus on, e.g., sample type, sample handling and analytical variation. Examples underlining the importance of including laboratory items are given. Conclusions: Inclusion of laboratory medicine specialist in the guideline development process may increase the focus on important laboratory related items even if this information is usually limited. Two checklists are suggested to help guideline developers to cover all important topics related to laboratory testing.

26 December 2022 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
PCPaul St Georges University of Collinson
Paul St Georges University of Collinson
KAKristin M. Aakre
Kristin M. Aakre
ASAmy Saenger
Amy Saenger
RBRick Body
Rick Body
OHOle Hammarsten
Ole Hammarsten
FAFred S. Apple
Fred S. Apple
The International Federation of Clinical Chemistry and Laboarator Medicine (IFCC) Committee on Clinical Applications of Cardiac Bio-Markers (C-CB) has provided evidence-based educational resources to aid and improve the understanding of important analytical and clinical aspects of cardiac biomarkers. The present IFCC C-CB educational report focuses on recommendations for appropriate use, analytical performance, and gaps in clinical studies related to the use of cardiac troponin (cTn) by point of care (POC) measurement, often referred to as a point of care testing (POCT). The use of high-sensitivity (hs)-cTn POC devices in accelerated diagnostic protocols used in emergency departments or outpatient clinics investigating acute coronary syndrome has the potential for improved efficacy, reduction of length of stay and reduced costs in the health care system. POCT workflow integration includes location of the instrument, assignment of collection and testing responsibility to (non-lab) staff, instrument maintenance, in-service and recurrent training, quality control, proficiency assessments, discrepant result trapping, and troubleshooting and inventory management.

1 April 2018 in Clinica Chimica Acta
Verified
Journal Article
Closed access
ØSØyvind Skadberg
Øyvind Skadberg
ØKØyunn Kleiven
Øyunn Kleiven
SØStein Ørn
Stein Ørn
MBMagnus Bjørkavoll-Bergseth
Magnus Bjørkavoll-Bergseth
TMTor H. Melberg
Tor H. Melberg
KAKristin M. Aakre
Kristin M. Aakre